EA201891048A1 - ANTIBODY, NEUTRALIZING RESPIRATORY-SYNCTIAL HUMAN VIRUS - Google Patents

ANTIBODY, NEUTRALIZING RESPIRATORY-SYNCTIAL HUMAN VIRUS

Info

Publication number
EA201891048A1
EA201891048A1 EA201891048A EA201891048A EA201891048A1 EA 201891048 A1 EA201891048 A1 EA 201891048A1 EA 201891048 A EA201891048 A EA 201891048A EA 201891048 A EA201891048 A EA 201891048A EA 201891048 A1 EA201891048 A1 EA 201891048A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synctial
antibody
human virus
relates
antibodies
Prior art date
Application number
EA201891048A
Other languages
Russian (ru)
Other versions
EA039222B1 (en
Inventor
Калпит А. Вора
Кара С. Кокс
Аймин Танг
Чжифэн Чен
Дэниэл Дистефано
Лань ЧЖАН
Хуа-Поо Су
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Priority claimed from PCT/US2016/058975 external-priority patent/WO2017075124A1/en
Publication of EA201891048A1 publication Critical patent/EA201891048A1/en
Publication of EA039222B1 publication Critical patent/EA039222B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Изобретение относится к моноклональным антителам, имеющим высокие титры при нейтрализации РСВ. Изобретение также относится к выделенным нуклеиновым кислотам, кодирующим антитела по изобретению, и клеткам-хозяевам, трансформированным ими. Кроме того, изобретение относится к диагностическим, профилактическим и терапевтическим способам с использованием антител и нуклеиновых кислот по изобретению, в частности, в качестве пассивного иммунотерапевтического средства для детей и пожилых людей.The invention relates to monoclonal antibodies having high titers in neutralizing RSV. The invention also relates to isolated nucleic acids encoding the antibodies of the invention, and host cells transformed by them. In addition, the invention relates to diagnostic, prophylactic and therapeutic methods using the antibodies and nucleic acids of the invention, in particular, as a passive immunotherapeutic agent for children and the elderly.

EA201891048A 2016-07-27 2016-10-27 Antibody neutralizing human respiratory syncytial virus EA039222B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367359P 2016-07-27 2016-07-27
PCT/US2016/058975 WO2017075124A1 (en) 2015-10-29 2016-10-27 Antibody neutralizing human respiratory syncytial virus

Publications (2)

Publication Number Publication Date
EA201891048A1 true EA201891048A1 (en) 2018-10-31
EA039222B1 EA039222B1 (en) 2021-12-20

Family

ID=80632889

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891048A EA039222B1 (en) 2016-07-27 2016-10-27 Antibody neutralizing human respiratory syncytial virus

Country Status (1)

Country Link
EA (1) EA039222B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7075496A (en) * 1995-09-18 1997-04-09 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof

Also Published As

Publication number Publication date
EA039222B1 (en) 2021-12-20

Similar Documents

Publication Publication Date Title
JOP20200091A1 (en) Antibody neutralizing human respiratory syncytial virus
EA201892793A1 (en) ANTI-HLA-G SPECIFIC ANTIBODIES
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
ZA201807467B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
EA201890630A1 (en) ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
EA201890874A1 (en) ANTIBODIES THAT EFFECTIVELY NEUTRALIZE THE HEPATITIS B VIRUS AND THEIR USE
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
MX2021010519A (en) Prefusion rsv f proteins and their use.
EA201791086A1 (en) HUMAN ANTIBODIES AGAINST HEMAGGLUTININ VIRUS OF FLU
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
MX352338B (en) Neutralizing anti-influenza a virus antibodies and uses thereof.
EA201290955A1 (en) FULL-DIMENSIONAL IGG ISOTYPE IMMUNOGLOBULINS, CAPABLE TO RECOGNITION OF NEUTRALIZING EPITOPE IN THE REGION OF THE HEMAGGLUTININ STEM OF VARIOUS SUBTIPS, AND THEIR USE IN THE QUALITY OF THE VARIABLES OF THE DIFFERENT SUBTYPES, AND THEIR USE AS A VARIETY OF THE STEM
WO2014200898A3 (en) Cmv neutralizing antigen binding proteins
WO2013059524A3 (en) Antibodies directed against influenza
WO2013188870A3 (en) IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EA201892313A1 (en) HUMANIZED ANTIBODIES AGAINST CLEVER-1 AND THEIR APPLICATION
WO2014040025A3 (en) Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
EA201891048A1 (en) ANTIBODY, NEUTRALIZING RESPIRATORY-SYNCTIAL HUMAN VIRUS
WO2017192946A8 (en) Dna monoclonal antibodies targeting influenza virus
EA201390735A1 (en) VACCINE COMPOSITIONS WITH FRAGMENTS OF SPLITTED IMMUNOGLOBULINS
EA201270794A1 (en) MARKER VACCINE AGAINST CLASSICAL SWINE FEVER
AR106471A1 (en) ANTIBODY THAT NEUTRALIZES THE HUMAN SYNTHETIC RESPIRATORY VIRUS
WO2019075300A3 (en) Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof